Because of increasingly widespread sedentary lifestyles and diets high in fat and sugar, the global diabetes and obesity epidemic continues to grow unabated. A substantial body of evidence has been accumulated which associates diabetes and obesity to dramatically higher risk of cancer development, particularly in the liver and gastrointestinal tract. Additionally, diabetic and obese individuals have been shown to suffer from dysregulation of bile acid (BA) homeostasis and dysbiosis of the intestinal microbiome. Abnormally elevated levels of cytotoxic secondary BAs and a pro-inflammatory shift in gut microbial profile have individually been linked to numerous enterohepatic diseases including cancer. However, recent findings have implicated a detrimental interplay between BA dysregulation and intestinal dysbiosis that promotes carcinogenesis along the gut–liver axis. This review seeks to examine the currently investigated interactions between the regulation of BA metabolism and activity of the intestinal microbiota and how these interactions can drive cancer formation in the context of diabesity. The precarcinogenic effects of BA dysregulation and gut dysbiosis including excessive inflammation, heightened oxidative DNA damage, and increased cell proliferation are discussed. Furthermore, by focusing on the mediatory roles of BA nuclear receptor farnesoid x receptor, ileal transporter apical sodium dependent BA transporter, and G-coupled protein receptor TGR5, this review attempts to connect BA dysregulation, gut dysbiosis, and enterohepatic carcinogenesis at a mechanistic level. A better understanding of the intricate interplay between BA homeostasis and gut microbiome can yield novel avenues to combat the impending rise in diabesity-related cancers.
ShawJESicreeRAZimmetPZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract2010; 87: 4–14.
2.
EckelRHKahnSEFerranniniEGoldfineABNathanDMSchwartzMWSmithRJSmithSREndocrineSocietyAmerican DiabetesAssociation. European Association for the Study of Diabetes, Obesity and type 2 diabetes: What can be unified and what needs to be individualized?Diabetes Care2011; 34: 1424–30.
3.
LarssonSCWolkA. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr2007; 86: 556–65.
4.
LarssonSCWolkA. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer2007; 97: 1005–8.
5.
GiovannucciEHarlanDMArcherMCBergenstalRMGapsturSMHabelLAPollakMRegensteinerJGYeeD. Diabetes and cancer: A consensus report. Diabetes Care2010; 33: 1674–85.
6.
CalleEEKaaksR. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer2004; 4: 579–91.
7.
TsuganeSInoueM. Insulin resistance and cancer: epidemiological evidence. Cancer Sci2010; 101: 1073–9.
8.
BaranovaAGowderSJSchlauchKElarinyHCollantesRAfendyAOngJPGoodmanZChandhokeVYounossiZM. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg2006; 16: 1118–25.
9.
FentonJIBirminghamJMHurstingSDHordNG. Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc Min/+ colon epithelial cells. Int J Cancer2008; 122: 2437–45.
10.
KamadaYMatsumotoHTamuraSFukushimaJKisoSFukuiKIguraTMaedaNKiharaSFunahashiTMatsuzawaYShimomuraIHayashiN. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol2007; 47: 556–64.
11.
KumorADanielPPietruczukMMalecka-PanasE. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis2009; 24: 275–81.
12.
HolmesELiJVAthanasiouTAshrafianHNicholsonJK. Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. Trends Microbiol2011; 19: 349–59.
13.
Shackel NA, Vadas MA, Gamble JR, McCaughan GW. Beyond liver fibrosis: Hepatic stellate cell senescence links obesity to liver cancer via the microbiome. Hepatology 2013;59:2413–5.
14.
BernsteinHBernsteinCPayneCMDvorakovaKGarewalH. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res2005; 589: 47–65.
15.
TraunerMClaudelTFickertPMoustafaTWagnerM. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis2010; 28: 220–4.
SayinSIWahlstromAFelinJJanttiSMarschallHUBambergKAngelinBHyotylainenTOresicMBackhedF. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab2013; 17: 225–35.
18.
IslamKBFukiyaSHagioMFujiiNIshizukaSOokaTOguraYHayashiTYokotaA. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology2011; 141: 1773–81.
19.
Ridlon JM, Alves JM, Hylemon PB, Bajaj JS. Cirrhosis, bile acids, and gut microbiota: Unraveling a complex relationship. Gut Microbes 2013;4:382--7.
20.
ChiangJY. Regulation of bile acid synthesis. Front Biosci1998; 3: d176–93.
21.
GoodwinBJonesSAPriceRRWatsonMAMcKeeDDMooreLBGalardiCWilsonJGLewisMCRothMEMaloneyPRWillsonTMKliewerSA. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell2000; 6: 517–26.
22.
WeiJQiu deKMaX. Bile acids and insulin resistance: Implications for treating nonalcoholic fatty liver disease. J Dig Dis2009; 10: 85–90.
23.
MatsubaraTLiFGonzalezFJ. FXR signaling in the enterohepatic system. Mol Cell Endocrinol2013; 368: 17–29.
ZhangYLeeFYBarreraGLeeHValesCGonzalezFJWillsonTMEdwardsPA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA2006; 103: 1006–11.
26.
CiprianiSMencarelliAPalladinoGFiorucciS. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res2010; 51: 771–84.
27.
RengaBMencarelliAVavassoriPBrancaleoneVFiorucciS. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim Biophys Acta2010; 1802: 363–72.
28.
Duran-SandovalDMautinoGMartinGPercevaultFBarbierOFruchartJCKuipersFStaelsB. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes2004; 53: 890–8.
29.
KirSZhangYGerardRDKliewerSAMangelsdorfDJ. Nuclear receptors HNF4alpha and LRH-1 cooperate in regulating Cyp7a1 in vivo. J Biol Chem2012; 287: 41334–41.
30.
YangJIYoonJHMyungSJGwakGYKimWChungGELeeSHLeeSMKimCYLeeHS. Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes. Biochem Biophys Res Commun2007; 361: 156–61.
31.
NomotoMMiyataMYinSKurataYShimadaMYoshinariKGonzalezFJSuzukiKShibasakiSKurosawaTYamazoeY. Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor. Biol Pharm Bull2009; 32: 172–8.
32.
Li G, Zhu Y, Tawfik O, Kong B, Williams JA, Zhan L, Kassel KM, Luyendyk JP, Wang L, Guo GL. Mechanisms of STAT3 activation in the liver of FXR knockout mice. Am J Physiol Gastrointest Liver Physiol 2013;305:G829--37.
33.
WangYDChenWDWangMYuDFormanBMHuangW. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology2008; 48: 1632–43.
34.
WolfeAThomasAEdwardsGJasejaRGuoGLApteU. Increased activation of the Wnt/beta-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther2011; 338: 12–21.
35.
LiuNMengZLouGZhouWWangXZhangYZhangLLiuXYenYLaiLFormanBMXuZXuRHuangW. Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1alpha regulation of FXR expression. Mol Endocrinol2012; 26: 775–85.
36.
ShimizuMTanakaTMoriwakiH. Obesity and hepatocellular carcinoma: Targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol2013; 35: 191–202.
37.
JiangYIakovaPJinJSullivanESharinVHongIHAnakkSMayorADarlingtonGFinegoldMMooreDTimchenkoNA. Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer. Hepatology2013; 57: 1098–106.
38.
VaqueroJBrizOHerraezEMuntaneJMarinJJ. Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds. Biochim Biophys Acta2013; 1833: 2212–9.
39.
VavassoriPMencarelliARengaBDistruttiEFiorucciS. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol2009; 183: 6251–61.
40.
GadaletaRMvan ErpecumKJOldenburgBWillemsenECRenooijWMurzilliSKlompLWSiersemaPDSchipperMEDaneseSPennaGLavernyGAdoriniLMoschettaAvan MilSW. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut2011; 60: 463–72.
41.
KuribayashiHMiyataMYamakawaHYoshinariKYamazoeY. Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling. Eur J Pharmacol2012; 697: 132–8.
42.
RengaBMencarelliACiprianiSD’AmoreCCarinoABrunoAFrancisciDZampellaADistruttiEFiorucciS. The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. PLoS One2013; 8: e54472–e54472.
43.
ZhangYGongWDaiSHuangGShenXGaoMXuZZengYHeF. Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol Cancer Res2012; 10: 516–22.
44.
FujinoTTakeuchiAMaruko-OhtakeAOhtakeYSatohJKobayashiTTanakaTItoHSakamakiRKashimuraRAndoKNishimaki-MogamiTOhkuboYKitamuraNSatoRKikugawaKHayakawaM. Critical role of farnesoid X receptor for hepatocellular carcinoma cell proliferation. J Biochem2012; 152: 577–86.
45.
LaxSSchauerGPreinKKapitanMSilbertDBergholdABergerATraunerM. Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. Int J Cancer2012; 130: 2232–9.
46.
Van MilSWMilonaADixonPHMullenbachRGeenesVLChambersJShevchukVMooreGELammertFGlantzAGMattssonLAWhittakerJParkerMGWhiteRWilliamsonC. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology2007; 133: 507–16.
47.
MarzoliniCTironaRGGervasiniGPoonkuzhaliBAssemMLeeWLeakeBFSchuetzJDSchuetzEGKimRB. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol2007; 21: 1769–80.
48.
AttinkaraRMwinyiJTruningerKRegulaJGajPRoglerGKullak-UblickGAElorantaJJSwissI.B.D. C.S.G. Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. BMC Res Notes2012; 5: 461–461.
49.
Claro da SilvaTPolliJESwaanPW. The solute carrier family 10 (SLC10): Beyond bile acid transport. Mol Aspects Med2013; 34: 252–69.
50.
KostersAKarpenSJ. Bile acid transporters in health and disease. Xenobiotica2008; 38: 1043–71.
51.
AlrefaiWASarwarZTyagiSSaksenaSDudejaPKGillRK. Cholesterol modulates human intestinal sodium-dependent bile acid transporter. Am J Physiol Gastrointest Liver Physiol2005; 288: G978–85.
52.
NeimarkEChenFLiXShneiderBL. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology2004; 40: 149–56.
53.
LefebvrePCariouBLienFKuipersFStaelsB. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev2009; 89: 147–91.
54.
ThomasCLandrierJFGaillardDGroberJMonnotMCAthiasABesnardP. Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: Molecular mechanism and physiological consequences. Gut2006; 55: 1321–31.
55.
AlrefaiWAGillRK. Bile acid transporters: Structure, function, regulation and pathophysiological implications. Pharm Res2007; 24: 1803–23.
56.
DawsonPAHaywoodJCraddockALWilsonMTietjenMKluckmanKMaedaNParksJS. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem2003; 278: 33920–7.
57.
ChenLYaoXYoungAMcNultyJAndersonDLiuYNystromCCroomDRossSCollinsJRajpalDHamletKSmithCGedulinB. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab2012; 302: E68–76.
58.
LundasenTAnderssonEMSnaithMLindmarkHLundbergJOstlund-LindqvistAMAngelinBRudlingM. Inhibition of intestinal bile acid transporter Slc10a2 improves triglyceride metabolism and normalizes elevated plasma glucose levels in mice. PLoS One2012; 7: e37787–e37787.
59.
MiyataMYamakawaHHamatsuMKuribayashiHTakamatsuYYamazoeY. Enterobacteria modulate intestinal bile acid transport and homeostasis through apical sodium-dependent bile acid transporter (SLC10A2) expression. J Pharmacol Exp Ther2011; 336: 188–96.
60.
MiyataMYamakawaHHayashiKKuribayashiHYamazoeYYoshinariK. Ileal apical sodium-dependent bile acid transporter protein levels are down-regulated through ubiquitin-dependent protein degradation induced by bile acids. Eur J Pharmacol2013; 714: 507–14.
61.
AnnabaFSarwarZGillRKGhoshASaksenaSBorthakurAHechtGADudejaPKAlrefaiWA. Enteropathogenic Escherichia coli inhibits ileal sodium-dependent bile acid transporter ASBT. Am J Physiol Gastrointest Liver Physiol2012; 302: G1216–22.
62.
WangWXueSInglesSAChenQDiepATFranklHDStolzAHaileRW. An association between genetic polymorphisms in the ileal sodium-dependent bile acid transporter gene and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev2001; 10: 931–6.
63.
RennerOHarschSSchaeffelerEWinterSSchwabMKrawczykMRosendahlJWittenburgHLammertFStangeEF. A variant of the SLC10A2 gene encoding the apical sodium-dependent bile acid transporter is a risk factor for gallstone disease. PLoS One2009; 4: e7321–e7321.
64.
HoRHLeakeBFUrquhartBLGregorJCDawsonPAKimRB. Functional characterization of genetic variants in the apical sodium-dependent bile acid transporter (ASBT; SLC10A2). J Gastroenterol Hepatol2011; 26: 1740–8.
65.
ChenXLouGMengZHuangW. TGR5: A novel target for weight maintenance and glucose metabolism. Exp Diabetes Res2011; 2011: 853501–853501.
66.
PolsTWNoriegaLGNomuraMAuwerxJSchoonjansK. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol2011; 54: 1263–72.
67.
PotthoffMJPottsAHeTDuarteJATaussigRMangelsdorfDJKliewerSABurgessSC. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol2013; 304: G371–80.
HarachTPolsTWNomuraMMaidaAWatanabeMAuwerxJSchoonjansK. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep2012; 2: 430–430.
70.
WatanabeMMorimotoKHoutenSMKaneko-IwasakiNSugizakiTHoraiYMatakiCSatoHMurahashiKAritaESchoonjansKSuzukiTItohHAuwerxJ. Bile acid binding resin improves metabolic control through the induction of energy expenditure. PLoS One2012; 7: e38286–e38286.
71.
UllmerCAlvarez SanchezRSprecherURaabSMatteiPDehmlowHSewingSIglesiasABeauchampJConde-KnapeK. Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release. Br J Pharmacol2013; 169: 671–84.
72.
WangYDChenWDYuDFormanBMHuangW. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology2011; 54: 1421–32.
73.
ChenWDYuDFormanBMHuangWWangYD. Deficiency of G-protein-coupled bile acid receptor Gpbar1 (TGR5) enhances chemically induced liver carcinogenesis. Hepatology2013; 57: 656–66.
74.
PeanNDoignonIGarcinIBesnardAJulienBLiuBBranchereauSSpraulAGuettierCHumbertLSchoonjansKRainteauDTordjmannT. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology2013; 58: 1451–60.
CiprianiSMencarelliAChiniMGDistruttiERengaBBifulcoGBaldelliFDoniniAFiorucciS. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One2011; 6: e25637–e25637.
77.
YonenoKHisamatsuTShimamuraKKamadaNIchikawaRKitazumeMTMoriMUoMNamikawaYMatsuokaKSatoTKoganeiKSugitaAKanaiTHibiT. TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn’s disease. Immunology2013; 139: 19–29.
78.
YasudaHHirataSInoueKMashimaHOhnishiHYoshibaM. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun2007; 354: 154–9.
79.
CaoWTianWHongJLiDTavaresRNobleLMossSFResnickMB. Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am J Physiol Gastrointest Liver Physiol2013; 304: G322–7.
80.
JensenDDGodfreyCBNiklasCCanalsMKocanMPooleDPMurphyJEAlemiFCottrellGSKorbmacherCLambertNABunnettNWCorveraCU. The bile acid receptor TGR5 does not interact with beta-arrestins or traffic to endosomes but transmits sustained signals from plasma membrane rafts. J Biol Chem2013; 288: 22942–60.
81.
CasaburiIAvenaPLanzinoMSisciDGiordanoFMarisPCatalanoSMorelliCAndoS. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation. Cell Cycle2012; 11: 2699–710.
82.
TatsugamiMItoMTanakaSYoshiharaMMatsuiHHarumaKChayamaK. Bile acid promotes intestinal metaplasia and gastric carcinogenesis. Cancer Epidemiol Biomarkers Prev2012; 21: 2101–7.
83.
HovJRKeitelVLaerdahlJKSpomerLEllinghausEElSharawyAMelumEBobergKMMankeTBalschunTSchrammCBergquistAWeismullerTGotthardtDRustCHenckaertsLOnnieCMWeersmaRKSterneckMTeufelARunzHStiehlAPonsioenCYWijmengaCVatnMHGroupISStokkersPCVermeireSMathewCGLieBABeuersUMannsMPSchreiberSSchrumpfEHaussingerDFrankeAKarlsenTH. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One2010; 5: e12403–e12403.
84.
FiorucciSCiprianiSMencarelliARengaBDistruttiEBaldelliF. Counter-regulatory role of bile acid activated receptors in immunity and inflammation. Curr Mol Med2010; 10: 579–95.
85.
BaptissartMVegaAMaqdasySCairaFBaronSLobaccaroJMVolleDH. Bile acids: From digestion to cancers. Biochimie2013; 95: 504–17.
86.
YokotaAFukiyaSIslamKBOokaTOguraYHayashiTHagioMIshizukaS. Is bile acid a determinant of the gut microbiota on a high-fat diet?Gut Microbes2012; 3: 455–9.
87.
LeyRE. Obesity and the human microbiome. Curr Opin Gastroenterol2010; 26: 5–11.
88.
TurnbaughPJHamadyMYatsunenkoTCantarelBLDuncanALeyRESoginMLJonesWJRoeBAAffourtitJPEgholmMHenrissatBHeathACKnightRGordonJI. A core gut microbiome in obese and lean twins. Nature2009; 457: 480–4.
89.
TurnbaughPJLeyREHamadyMFraser-LiggettCMKnightRGordonJI. The human microbiome project. Nature2007; 449: 804–10.
90.
DavidLAMauriceCFCarmodyRNGootenbergDBButtonJEWolfeBELingAVDevlinASVarmaYFischbachMABiddingerSBDuttonRJTurnbaughPJ. Diet rapidly and reproducibly alters the human gut microbiome. Nature2014; 505: 559–63.
91.
Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T, Bornstein SR. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: Correlation with inflammatory and metabolic parameters. Pharmacogenomics J 2012;13:514–22.
92.
MussoGGambinoRCassaderM. Obesity, diabetes, and gut microbiota: The hygiene hypothesis expanded?Diabetes Care2010; 33: 2277–84.
93.
RidauraVKFaithJJReyFEChengJDuncanAEKauALGriffinNWLombardVHenrissatBBainJRMuehlbauerMJIlkayevaOSemenkovichCFFunaiKHayashiDKLyleBJMartiniMCUrsellLKClementeJCVan TreurenWWaltersWAKnightRNewgardCBHeathACGordonJI. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science2013; 341: 1241214–1241214.
94.
HildebrandtMAHoffmannCSherrill-MixSAKeilbaughSAHamadyMChenYYKnightRAhimaRSBushmanFWuGD. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology2009; 137: 1716–24e1–2.
95.
LarsenNVogensenFKvan den BergFWNielsenDSAndreasenASPedersenBKAl-SoudWASorensenSJHansenLHJakobsenM. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One2010; 5: e9085–e9085.
TurnbaughPJLeyREMahowaldMAMagriniVMardisERGordonJI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature2006; 444: 1027–31.
98.
AngelakisEArmougomFMillionMRaoultD. The relationship between gut microbiota and weight gain in humans. Future Microbiol2012; 7: 91–109.
99.
DuncanSHLobleyGEHoltropGInceJJohnstoneAMLouisPFlintHJ. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes (Lond)2008; 32: 1720–4.
100.
FuretJPKongLCTapJPoitouCBasdevantABouillotJLMariatDCorthierGDoreJHenegarCRizkallaSClementK. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: Links with metabolic and low-grade inflammation markers. Diabetes2010; 59: 3049–57.
101.
KongLCTapJAron-WisnewskyJPellouxVBasdevantABouillotJLZuckerJDDoreJClementK. Gut microbiota after gastric bypass in human obesity: Increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr2013; 98: 16–24.
102.
LiFJiangCKrauszKWLiYAlbertIHaoHFabreKMMitchellJBPattersonADGonzalezFJ. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun2013; 4: 2384–2384.
103.
SongPZhangYKlaassenCD. Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice. Toxicol Sci2011; 123: 359–67.
104.
BuchwaldHEstokRFahrbachKBanelDJensenMDPoriesWJBantleJPSledgeI. Weight and type 2 diabetes after bariatric surgery: Systematic review and meta-analysis. Am J Med2009; 122: 248–256 e5.
105.
BeckmanLMBeckmanTRSibleySDThomasWIkramuddinSKelloggTAGhateiMABloomSRle RouxCWEarthmanCP. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery. J Parenter Enteral Nutr2011; 35: 169–80.
106.
KornerJBesslerMInabnetWTaverasCHolstJJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis2007; 3: 597–601.
107.
PattiMEHoutenSMBiancoACBernierRLarsenPRHolstJJBadmanMKMaratos-FlierEMunECPihlajamakiJAuwerxJGoldfineAB. Serum bile acids are higher in humans with prior gastric bypass: Potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring)2009; 17: 1671–7.
108.
WerlingMVincentRPCrossGFMarschallHUFandriksLLonrothHTaylorDRAlaghband-ZadehJOlbersTLe RouxCW. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scand J Gastroenterol2013; 48: 1257–64.
109.
ZhangHDiBaiseJKZuccoloAKudrnaDBraidottiMYuYParameswaranPCrowellMDWingRRittmannBEKrajmalnik-BrownR. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci USA2009; 106: 2365–70.
110.
PournarasDJGlicksmanCVincentRPKuganolipavaSAlaghband-ZadehJMahonDBekkerJHGhateiMABloomSRWaltersJRWelbournRle RouxCW. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology2012; 153: 3613–9.
111.
ZarrinparALoombaR. Review article: The emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther2012; 36: 909–21.
112.
KohliRKirbyMSetchellKDJhaPKlustaitisKWoollettLAPflugerPTBalistreriWFTsoPJandacekRJWoodsSCHeubiJETschoepMHD’AlessioDAShroyerNFSeeleyRJ. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol2010; 299: G652–60.
113.
Ahmad NN, Pfalzer A, Kaplan LM. Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity. Int J Obes (Lond) 2013;37:1553–9.
114.
LiouAPPaziukMLuevanoJMJrMachineniSTurnbaughPJKaplanLM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med2013; 5: 178ra41–178ra41.
115.
SokolHPigneurBWatterlotLLakhdariOBermudez-HumaranLGGratadouxJJBlugeonSBridonneauCFuretJPCorthierGGrangetteCVasquezNPochartPTrugnanGThomasGBlottiereHMDoreJMarteauPSeksikPLangellaP. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA2008; 105: 16731–6.
116.
LiTFranclJMBoehmeSOchoaAZhangYKlaassenCDEricksonSKChiangJY. Glucose and insulin induction of bile acid synthesis: Mechanisms and implication in diabetes and obesity. J Biol Chem2012; 287: 1861–73.
117.
FoutsDETorralbaMNelsonKEBrennerDASchnablB. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol2012; 56: 1283–92.
118.
InagakiTMoschettaALeeYKPengLZhaoGDownesMYuRTSheltonJMRichardsonJARepaJJMangelsdorfDJKliewerSA. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA2006; 103: 3920–5.
119.
MunchAStromMSoderholmJD. Dihydroxy bile acids increase mucosal permeability and bacterial uptake in human colon biopsies. Scand J Gastroenterol2007; 42: 1167–74.
120.
RaimondiFSantoroPBaroneMVPappacodaSBarrettaMLNanayakkaraMApicellaCCapassoLPaludettoR. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol2008; 294: G906–13.
121.
StenmanLKHolmaREggertAKorpelaR. A novel mechanism for gut barrier dysfunction by dietary fat: Epithelial disruption by hydrophobic bile acids. Am J Physiol Gastrointest Liver Physiol2013; 304: G227–34.
122.
YoshimotoSLooTMAtarashiKKandaHSatoSOyadomariSIwakuraYOshimaKMoritaHHattoriMHondaKIshikawaYHaraEOhtaniN. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature2013; 499: 97–101.
123.
AllenKJaeschkeHCoppleBL. Bile acids induce inflammatory genes in hepatocytes: A novel mechanism of inflammation during obstructive cholestasis. Am J Pathol2011; 178: 175–86.
124.
RavussinYKorenOSporALeDucCGutmanRStombaughJKnightRLeyRELeibelRL. Responses of gut microbiota to diet composition and weight loss in lean and obese mice. Obesity (Silver Spring)2012; 20: 738–47.
125.
GabeleEFrohMArteelGEUesugiTHellerbrandCScholmerichJBrennerDAThurmanRGRippeRA. TNFalpha is required for cholestasis-induced liver fibrosis in the mouse. Biochem Biophys Res Commun2009; 378: 348–53.
126.
HartmannPHaimerlMMazagovaMBrennerDASchnablB. Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology2012; 143: 1330–40 e1.
127.
ZhaoHYWangHJLuZXuSZ. Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis2004; 5: 64–7.
128.
CaiWJWangMJJuLHWangCZhuYC. Hydrogen sulfide induces human colon cancer cell proliferation: Role of Akt, ERK and p21. Cell Biol Int2010; 34: 565–72.
129.
DevkotaSWangYMuschMWLeoneVFehlner-PeachHNadimpalliAAntonopoulosDAJabriBChangEB. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature2012; 487: 104–8.
130.
SzaboCHellmichMR. Endogenously produced hydrogen sulfide supports tumor cell growth and proliferation. Cell Cycle2013; 12: 2915–6.
131.
KakiyamaGPandakWMGillevetPMHylemonPBHeumanDMDaitaKTakeiHMutoANittonoHRidlonJMWhiteMBNobleNAMonteithPFuchsMThackerLRSikaroodiMBajajJS. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol2013; 58: 949–55.
132.
De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, Mingarelli E, Facinelli B, Magi G, Palmieri C, Marzioni M, Benedetti A, Svegliati-Baroni G. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury. Hepatology 2013;59:1738–49.
133.
HuBElinavEHuberSBoothCJStrowigTJinCEisenbarthSCFlavellRA. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci USA2010; 107: 21635–40.
134.
KayagakiNWongMTStoweIBRamaniSRGonzalezLCAkashi-TakamuraSMiyakeKZhangJLeeWPMuszynskiAForsbergLSCarlsonRWDixitVM. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science2013; 341: 1246–9.
PussinenPJHavulinnaASLehtoMSundvallJSalomaaV. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care2011; 34: 392–7.
137.
MaKSahaPKChanLMooreDD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest2006; 116: 1102–9.
138.
Li Z, Xue J, Chen P, Chen L, Yan SP, Liu L. Prevalence of nonalcoholic fatty liver disease in mainland of China: A meta-analysis of published studies. J Gastroenterol Hepatol 2013;29:42–51.
139.
ParkJSSeoJHYounHS. Gut microbiota and clinical disease: Obesity and nonalcoholic fatty liver disease. Pediatr Gastroenterol Hepatol Nutr2013; 16: 22–27.
140.
JonssonJRBarrieHDO’RourkePCloustonADPowellEE. Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology2008; 48: 80–7.
DvorakKPayneCMChavarriaMRamseyLDvorakovaBBernsteinHHolubecHSamplinerREGuyNCondonABernsteinCGreenSBPrasadAGarewalHS. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: Relevance to the pathogenesis of Barrett’s oesophagus. Gut2007; 56: 763–71.
143.
HuoXJuergensSZhangXRezaeiDYuCStrauchEDWangJYChengEMeyerFWangDHZhangQSpechlerSJSouzaRF. Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-kappaB activation in benign Barrett’s epithelial cells. Am J Physiol Gastrointest Liver Physiol2011; 301: G278–86.
144.
JollyAJWildCPHardieLJ. Sodium deoxycholate causes nitric oxide mediated DNA damage in oesophageal cells. Free Radic Res2009; 43: 234–40.
145.
SmithAFLongpreJLooG. Inhibition by zinc of deoxycholate-induced apoptosis in HCT-116 cells. J Cell Biochem2012; 113: 650–7.
146.
JenkinsGJCroninJAlhamdaniARawatND’SouzaFThomasTEltahirZGriffithsAPBaxterJN. The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-kappaB activation in oesophageal cells, with a mechanism of action involving ROS. Mutagenesis2008; 23: 399–405.
147.
LiaoMZhaoJWangTDuanJZhangYDengX. Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells. Mol Cancer2011; 10: 44–44.
148.
RoloAPPalmeiraCMHolyJMWallaceKB. Role of mitochondrial dysfunction in combined bile acid-induced cytotoxicity: The switch between apoptosis and necrosis. Toxicol Sci2004; 79: 196–204.
149.
BaysHE. Long-term (52–78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients. Diabetes Metab Syndr Obes2012; 5: 125–34.
150.
BeysenCMurphyEJDeinesKChanMTsangEGlassATurnerSMProtasioJRiiffTHellersteinMK. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: A randomised controlled study. Diabetologia2012; 55: 432–42.
151.
GoldfineABFonsecaVAJonesMRWangACFordDMTruittKE. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res2010; 42: 23–30.
SatoHMacchiaruloAThomasCGioielloAUneMHofmannAFSaladinRSchoonjansKPellicciariRAuwerxJ. Novel potent and selective bile acid derivatives as TGR5 agonists: Biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem2008; 51: 1831–41.
154.
WuWTChengHCChenHL. Ameliorative effects of konjac glucomannan on human faecal beta-glucuronidase activity, secondary bile acid levels and faecal water toxicity towards Caco-2 cells. Br J Nutr2011; 105: 593–600.
155.
BindelsLBPorporatoPDewulfEMVerraxJNeyrinckAMMartinJCScottKPBuc CalderonPFeronOMuccioliGGSonveauxPCaniPDDelzenneNM. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br J Cancer2012; 107: 1337–44.
156.
Serban DE. Gastrointestinal cancers: Influence of gut microbiota, probiotics and prebiotics. Cancer Lett 2013;345:258–70.
157.
WollowskiIRechkemmerGPool-ZobelBL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr2001; 73: 451S–5S.
158.
SlavinJ. Fiber and prebiotics: Mechanisms and health benefits. Nutrients2013; 5: 1417–35.
159.
DavisLMMartinezIWalterJGoinCHutkinsRW. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. PLoS One2011; 6: e25200–e25200.
160.
LarrosaMYanez-GasconMJSelmaMVGonzalez-SarriasATotiSCeronJJTomas-BarberanFDolaraPEspinJC. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem2009; 57: 2211–20.
161.
NeyrinckAMVan HeeVFBindelsLBDe BackerFCaniPDDelzenneNM. Polyphenol-rich extract of pomegranate peel alleviates tissue inflammation and hypercholesterolaemia in high-fat diet-induced obese mice: Potential implication of the gut microbiota. Br J Nutr2013; 109: 802–9.
162.
ZampaASilviSFabianiRMorozziGOrpianesiCCresciA. Effects of different digestible carbohydrates on bile acid metabolism and SCFA production by human gut micro-flora grown in an in vitro semi-continuous culture. Anaerobe2004; 10: 19–26.
163.
PedersenMHLauritzenLHellgrenLI. Fish oil combined with SCFA synergistically prevent tissue accumulation of NEFA during weight loss in obese mice. Br J Nutr2011; 106: 1449–56.
164.
WhelanKQuigleyEM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol2013; 29: 184–9.
165.
KelishadiRFarajianSMirlohiM. Probiotics as a novel treatment for non-alcoholic fatty liver disease; a systematic review on the current evidences. Hepat Mon2013; 13: e7233–e7233.
166.
MaYYLiLYuCHShenZChenLHLiYM. Effects of probiotics on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol2013; 19: 6911–8.
167.
HakanssonABranningCMolinGAdawiDHagslattMLJeppssonBNymanMAhrneS. Blueberry husks and probiotics attenuate colorectal inflammation and oncogenesis, and liver injuries in rats exposed to cycling DSS-treatment. PLoS One2012; 7: e33510–e33510.
168.
Raso GM, Simeoli R, Iaconoa A, Santoroa A, Ameroa P, Paciellob O, Russoa R, D’Agostinoa G, Di Costanzoc M, Cananic RB, Calignanoa A, Melia R. Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll like receptor expression in rats fed a high fat diet. J Nutr Biochem 2013;25:81–90.
169.
LiuQDuanZPHaDKBengmarkSKurtovicJRiordanSM. Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441–9.
170.
OkazakiYUtamaZSuidasariSZhangPYanakaNTomotakeHSakaguchiEKatoN. Consumption of vitamin B(6) reduces fecal ratio of lithocholic acid to deoxycholic acid, a risk factor for colon cancer, in rats fed a high-fat diet. J Nutr Sci Vitaminol (Tokyo)2012; 58: 366–70.
171.
OkazakiYSitanggangNVSatoSOhnishiNInoueJIguchiTWatanabeTTomotakeHHaradaKKatoN. Burdock fermented by Aspergillus awamori elevates cecal Bifidobacterium, and reduces fecal deoxycholic acid and adipose tissue weight in rats fed a high-fat diet. Biosci Biotechnol Biochem2013; 77: 53–7.
